Buscar en
Revista de Psiquiatría y Salud Mental
Toda la web
Inicio Revista de Psiquiatría y Salud Mental Amerindians may need clozapine dosing similar to that of Asians
Información de la revista
Vol. 14. Núm. 3.
Páginas 177-179 (Julio - Septiembre 2021)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 14. Núm. 3.
Páginas 177-179 (Julio - Septiembre 2021)
Scientific letter
Acceso a texto completo
Amerindians may need clozapine dosing similar to that of Asians
Los amerindios pueden necesitar las mismas bajas dosis de clozapina que los asiáticos
Visitas
830
Dinora F. González-Esquivela, Helgi Jung-Cooka,b, Trino Baptistac, Jose de Leond,e,f,
Autor para correspondencia
jdeleon@uky.edu

Corresponding author.
a Instituto Nacional de Neurología y Neurocirugía, México, D.F., Mexico
b Facultad de Química, Universidad Nacional Autónoma de México (UNAM), México, D.F., Mexico
c Department of Physiology, Los Andes University Medical School, Mérida, Venezuela
d Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA
e Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain
f Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Comparing mean clozapine C/D ratios after stratification by sex and smoking status in 5 Asian samples (N=508) and in a study in Mexico City (N=52a).
Texto completo
Dear Editor:

Clozapine is mainly metabolized by the cytochrome 1A2 (CYP1A2). CYP1A2 activity ranges from lowest in female non-smokers to highest in male smokers (estrogens are inhibitors and smoking is an inducer). To reach a therapeutic response requires 350ng/ml of serum clozapine concentration. The concentration-to-dose (C/D) ratio1 represents the linear relationship between clozapine dose and concentration.1 A very high C/D ratio indicates a poor metabolizer (PM) phenotype1,2 which can be explained by a potent inhibitor such as fluvoxamine, systemic inflammation and possibly obesity.1,2 After excluding non-adherence, a very low clozapine C/D ratio indicates an ultrarapid metabolizer (UM) phenotype, possibly explained by powerful inducers such as carbamazepine.2 Valproate is usually a mild inducer or inhibitor.1,2

Having less CYP1A2 activity than Caucasians, Asians need lower clozapine doses according to: (1) a meta-analysis,3 (2) a study of 5 Asian samples,2 and (3) a review of Asian dosing.4 Asians typically had clozapine C/D ratios from 1.2 to 2.4; Asian female non-smokers need 150mg/day and male smokers 300mg/day to reach 350ng/ml.4

The Amerindians (the indigenous people from the Americas) are of East Asian origin.4 This reanalysis of a sample5 from Mexico City with trough steady-state levels identified 52 Mexican average metabolizers after excluding potential clozapine PMs and UMs. We explored the clozapine dosages needed to reach 350ng/ml after stratification by sex and smoking (Table 1) and compared them with those from the 5 Asian samples.2

Table 1.

Comparing mean clozapine C/D ratios after stratification by sex and smoking status in 5 Asian samples (N=508) and in a study in Mexico City (N=52a).

Group  Sample  N  Age (year)  Dose (mg/day)  C/D ratioDose to reachb 
          Clozapine  Total  >350ng/ml (mg/day) 
♂ smokersBeijing 1  22  46.6  271  1.34±0.59  1.98±0.84  261 
Beijing 2  49  40.6  341  1.31±0.95  1.90±1.22  267 
Taipei  22  36.1  286  1.19±0.54  1.82±0.84  294 
Seoul  15  37.3  378  1.35±0.71  2.05±1.01  259 
Vellore  19  39.0  401  1.29±1.07    271 
Weighted mean  127      1.30    270 
Mexico City  10  38.9  275  1.29±0.88    280 
               
♀ smokersBeijing 1  54.6  301  1.50±0.58  1.90±1.22  NC 
Beijing 2  39.0  313  1.11±0.46  1.50±0.46  NC 
Taipei  36.3  325  1.24±0.48  2.03±0.80  NC 
Seoul  38  450  0.88  1.59  NC 
Weighted mean  11      1.30    270 
Mexico City  31.4  230  1.06±0.24    330 
               
♂ non-smokersBeijing 1  35  37.2  230  1.71±0.78  2.49±1.04  205 
Beijing 2  65  42.8  262  1.50±0.90  2.12±1.12  233 
Taipei  29  36.0  300  1.80±1.07  2.65±1.42  194 
Seoul  26  31.0  347  1.70±0.84  2.58±1.02  206 
Vellore  54  33.8  329  1.78±1.19    197 
Weighted mean  209      1.67    210 
Mexico City  18  35.7  294  1.76±1.13    199 
               
♀ non-smokersBeijing 1  64  45.1  202  2.11±0.74  2.97±1.00  166 
Beijing 2  75  46.5  297  2.03±1.64  2.87±2.12  172 
Taipei  31  39.1  254  2.38±1.41  3.38±2.00  147 
Seoul  25  32.4  282  2.41±1.02  3.72±1.52  145 
Vellore  28  36.2  323  1.85±1.16    189 
Weighted mean  233      2.12    166 
Mexico City  19  38.2  228  1.89±1.14    185 

C/D: concentration-to-dose; NC: not calculated due to the small sample size.

a

There were some patients with low doses (≤100mg/day), which is a problem because they were frequently used for an indication other than treatment-resistant schizophrenia and they appear to be associated with non-linear kinetics. After eliminating those patients contaminated with valproate and those with low doses (≤100mg/day), there were 52 patients left.

b

Mean dose needed to reach a concentration of 350ng/ml was calculated by dividing 350 by mean clozapine C/D ratio.

In 19 female non-smokers from Mexico City, the recommended average clozapine dosage was 185mg/day which is: (1) within the range of 145–189mg/day in similar Asians, and (2) not far from the weighted mean of 166mg/day in 233 Asian female non-smokers.

In 18 male non-smokers from Mexico City, the recommended average clozapine dosage was 199mg/day which is: (1) within the range of 194–205mg/day in similar Asians, and (2) not far from the weighted mean of 210mg/day in 209 Asian male non-smokers.

In 5 female smokers from Mexico City, the recommended average clozapine dosage was 330mg/day, but this group was too small for the authors to comment. In 10 male smokers from Mexico City, the recommended average clozapine dosage was 288mg/day which is: (1) within the range of 259–294 in similar Asians, and (2) not far from the weighted mean of 270mg/day in 127 Asian male smokers.

The sample of Mexico City fits within the Asian samples, suggesting similar clozapine clearance and need for the same low clozapine doses as Asians, but this data is limited by the lack of control for inflammation and obesity. Many American countries have populations of Amerindian origin; thus, future clozapine studies need to explore dosing after better control of variables and careful consideration of ancestry. Until then, psychiatrists working in the Americas may need to use clozapine doses ranging from 150 to 300mg/day for average-metabolizer patients with predominant Amerindian ancestry. These clozapine doses are lower than those required for average-metabolizer patients of Caucasian and/or African ancestry.1

Disclosure statement

This article was completed without any external funding. No commercial organizations had any role in the writing of this paper for publication. In the last 3 years, the authors had no conflicts of interest.

Acknowledgments

Lorraine Maw, M.A., at the Mental Health Research Center, helped with editing.

References
[1]
J. de Leon, C.J. Ruan, G. Schoretsanitis, C. De Las Cuevas.
A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology.
Psychother Psychosom, 89 (2020), pp. 200-214
[2]
C.J. Ruan, C.Y. Wang, Y.L. Tang, S.K. Lin, S.T. Lee, K.S. Hong, et al.
Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13.
J Clin Psychopharmacol, 39 (2019), pp. 644-648
[3]
C.J. Ruan, Y.N. Zang, C.Y. Wang, Y.H. Cheng, C. Sun, E. Spina, et al.
Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review.
J Clin Psychopharmacol, 39 (2019), pp. 135-144
[4]
J. de Leon, A.P. Rajkumar, A.R. Kaithi, G. Schoretsanitis, J.M. Kane, C.Y. Wang, et al.
Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview.
Indian J Psychol Med, 42 (2020), pp. 4-10
[5]
D.F. González-Esquivel, N. Castro, J. Ramírez-Bermúdez, V. Custodio, S. Rojas-Tomé, R. Castro-Román, et al.
Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
Arzneimittelforschung, 61 (2011), pp. 335-339
Copyright © 2020. SEP y SEPB
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos